Latest news with #AnikaTherapeutics
Yahoo
01-03-2025
- Business
- Yahoo
Is Anika Therapeutics, Inc. (ANIK) the Best Small Cap Pharma Stocks to Buy Now?
We recently compiled a list of the . In this article, we are going to take a look at where Anika Therapeutics, Inc. (NASDAQ:ANIK) stands against the other small cap pharma stocks. Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical industry. According to her, the industry might not perform poorly at least in the first half of this year. The effectiveness of obesity medications is still up for debate, though, as leading companies in the field have shown inconsistent results. Speaking about the tariffs, she stated that since some businesses assemble their products in the US after producing them overseas, their implementation raises several unanswered questions for the pharmaceutical industry. These businesses therefore have relatively low manufacturing costs, which is an important factor to take into account when assessing the effects of tariffs. She thought that these businesses could easily absorb the higher expense of the tariffs. The topic hasn't come up much on earnings calls this quarter, and the market is nearing the end of the reporting season. Eli Lilly's Chief Scientific Officer spoke with CNBC's Health and Pharma correspondent Angelica Peebles about the weight reduction industry. The domain presents opportunities for easier-to-use treatments, including tablets, and medications that help individuals lose weight, she noted based on the conversation. How much weight reduction users need to observe on top of what they already have is another topic of discussion about the subject. According to Dan Skovronsky, Chief Scientific Officer of Eli Lilly, the majority of the audience seems to benefit from medications that provide about 20% weight loss. According to him, the market for stronger medications that offer at least 25% is smaller. He also believed that the potential benefits of these weight reduction medications for a wide range of illnesses were the most fascinating thing he had witnessed in his work as a scientist and doctor. The patterns they have been observing in the answers from patients serve as their current source of knowledge. For our methodology, we selected stocks with a market capitalization between $250 million and $2 billion and ranked them based on the highest hedge fund sentiment according to Insider Monkey's database, as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A lab technician testing samples of regenerative solutions in an advanced lab Therapeutics, Inc. (NASDAQ:ANIK) is a global joint preservation company specializing in early intervention orthopedic care. It develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology, focusing on osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone-preserving joint technologies. The company's portfolio includes visco-supplementation treatments, joint implants, surgical instruments, and advanced wound care solutions. Anika Therapeutics, Inc. (NASDAQ:ANIK) reported its Q3 2024 financial results on October 31, 2024, showing a 7% revenue decline compared to the same period last year, with total revenue of $38.8 million. The decline was mainly due to reduced market access and competitive pricing pressures on their U.S. OA Pain Management products, particularly with their partner J&J Medtech, and weaker performance in the businesses they are exiting, like Arthrosurface and Parcus Medical. However, the company saw positive growth in its Regenerative Solutions, with revenue rising 17% to $2.7 million, driven by strong demand for the Integrity Implant System, which saw a 40%+ increase from the previous quarter. Anika Therapeutics, Inc. (NASDAQ:ANIK) posted a net loss of $29.9 million, or $2.03 per share, but its adjusted net income was a loss of $3.8 million, or $0.25 per share. Adjusted EBITDA stood at $5.4 million, and the company ended the quarter with a cash balance of $62.4 million. Despite the challenges, the corporation is focusing on its core hyaluronic acid (HA) technology and its Regenerative Solutions portfolio, divesting non-core assets like Arthrosurface and Parcus Medical to concentrate resources on higher-growth areas. Looking forward, the company sees strong potential in its products. The Integrity Implant System's growth signals promising prospects for its Regenerative Solutions. Additionally, the upcoming U.S. launch of Hyalofast and the potential approval of Cingal could provide significant growth opportunities, positioning Anika as a contender among the best pharmaceutical stocks. As of Q4 2024, 21 hedge funds held stakes in the company, as tracked by the Insider Monkey database. Overall ANIK ranks 12th on our list of the best small cap pharma stocks to buy now. While we acknowledge the potential of ANIK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ANIK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
25-02-2025
- Business
- Yahoo
Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference
BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on Monday, March 10, 2025 at 2:30pm PT / 5:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on the Events and Webcasts page under the Investors section of Anika Therapeutics' website and will be archived for 30 days following the presentation. For more information about this event or to schedule a one-on-one meeting with Anika's senior management, please contact Anika's Investor Relations at investorrelations@ About AnikaAnika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika's global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, TACTOSET, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use. For Investor Inquiries:Anika Therapeutics, Hall, 781-457-9554Director, Corporate Development and Investor Relationsinvestorrelations@ in to access your portfolio
